Hemolytic anemia following rasburicase administration: a review of published reports

The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG
Annhien P Nguyen, Genevieve L Ness

Abstract

Tumor lysis syndrome (TLS) is a potentially lethal complication of anticancer treatment. It is caused by the rapid death of malignant cells after initiation of cytotoxic therapy and is typically observed in patients with bulky or highly proliferative malignancies. Currently, rasburicase is one of the recommended therapies for this oncologic emergency. Although this drug is generally well tolerated among patients, there have been several reports of hemolytic anemia following rasburicase infusions. With drug-induced hemolytic anemia, the condition usually resolves shortly after the offending agent is discontinued. However, anemia that is prolonged or severe can lead to problems such as splenomegaly and rapid heart rate. This paper will review primary literature identified through PubMed, International Pharmaceutical Abstracts, and Embase concerning the incidence of hemolytic anemia with rasburicase use. From the available data, the occurrence of hemolytic anemia will be discussed.

References

Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H PuiG H Reaman
Feb 15, 2002·Clinical Journal of Oncology Nursing·Jeannine M Brant
Apr 6, 2006·Pediatrics·UNKNOWN American Academy of Pediatrics, Committee on Fetus and Newborn, UNKNOWN American College of Obstetricians and Gynecologists and Committee on Obstetric Practice
May 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierMitchell S Cairo
Oct 8, 2008·Haematologica·Patrizia TosiSante Tura
Oct 6, 2009·Indian Journal of Pediatrics·Pallab BasuHarendranath Das
Dec 17, 2009·Hematology·George Garratty
Mar 3, 2011·International Journal of Clinical Pharmacy·T BautersB De Moerloose
Dec 23, 2011·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·John S NgTosha A Egelund
Dec 5, 2012·Pediatrics·Patrizia ZaramellaLino Chiandetti

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.